- Ronopterin significantly reduces lactate levels in brain microdialysate from TBI patients reflecting energetic stability and neuroprotection during the early vulnerable phase
- The combined inhibition of nitric oxide synthesis and reduced lactate levels adds further insight into the mode of action of Ronopterin linked to improved outcome
- Low lactate levels add to the previously reported decreased glutamate release, lower treatment aggressiveness, and improved eGOS in Ronopterin treated patients after moderate and severe TBI
- The lactate-reducing potential of Ronopterin makes this iNOS inhibitor an interesting drug for acute and chronic neurologic diseases with NO-driven energetic impairment
- New patent filed for Ronopterin-mediated lactate reduction
Würzburg, Germany July 12, 2022: vasopharm GmbH, a privately-held biopharmaceutical company focusing on novel therapeutics to treat cerebrovascular diseases, today announces the results of significantly reduced brain microdialysate lactate levels in the phase 2 (NOSTRA) and phase 3 clinical trials (NOSTRA III) of Ronopterin (formerly VAS203) for the treatment of traumatic brain injury (TBI). These analyses expand on the improved clinical outcome, reduced aggressiveness of underlying treatment, and reduced brain microdialysate glutamate levels in patients with moderate and severe TBI with early infusion of Ronopterin after TBI. This reduction in lactate reflects biochemical protection from energetic impairment and cell damage caused by the inducible nitric oxide synthase (iNOS)-mediated increase in peroxynitrite and glutamate levels. Ronopterin has the potential to be the first successful drug therapy for TBI with meaningful signs of biochemical neuroprotection and improvements in neurologic outcome.